AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03254394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX regimen
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.
Study NCT02116855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: according to the efficacy of AJBRs
Study NCT01735474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual technique
Description: A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles.
Study NCT01735474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usual care
Study NCT01080131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
Study NCT01080131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Description: Triamcinolone acetonide 40 mg was supplied as a suspension.
Study NCT01080131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
Study NCT01080131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to triamcinolone acetonide
Description: Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Study NCT00387465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 30mg/m2
Description: Azacitidine 30mg/m2 subcutaneously (SQ)
Study NCT00387465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 7mg by mouth (PO) on days 3 and 10 of each cycle
Study NCT04083196 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03472651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
Study NCT03472651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
Study NCT04305418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness- Based Intervention
Description: Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment.
Study NCT02639546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Study NCT01143649 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: constraint induced movement therapy (CIMT)
Study NCT00387465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 40mg/m2
Description: Azacitidine 40mg/m2 SQ
Study NCT01143649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: Subjects will be stimulated at 15Hz for 20 minutes.
Study NCT01143649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Subjects will be stimulated at 15Hz for 20 minutes.
Study NCT00159796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine, 3 weeks
Study NCT00159796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 3 weeks
Study NCT00159796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 3 weeks
Study NCT02685033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Study NCT02685033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Study NCT03121963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone tablet
Study NCT03121963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen tablet
Study NCT03121963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin tablet
Study NCT03121963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib tablet
Study NCT03121963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: hydrocodone 5 mg/acetaminophen 325 mg tablet
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/ m2 by vein for 2 doses on Days -11 to -10.
Study NCT01390402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK cell infusion:
Description: Natural killer cell infusion will be administered by vein on Day -8.
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
Study NCT00225563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record
Description: e-prescribing methods
Study NCT00585260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: indirect mannitol challenge
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 2.5 mg/kg by vein for 3 doses on Days -3 to -1.
Study NCT01390402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic related Stem Cell Transplant
Description: Allogeneic related stem cell transplant by vein on day 0.
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein Days 1, 3 and 6 post transplant.
Study NCT01390402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
Study NCT03121950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The primary intervention is a dance class
Study NCT03121950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: the secondary intervention is listening to live music
Study NCT02308137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Simon-2-stage design for domperidone futility
Study NCT00798122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: intravascular ultrasound
Study NCT00798122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: cardiac MRI
Study NCT03055416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Men App Prototype
Description: Testing of app functionality
Study NCT02008734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Study NCT01960803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Electron Radiotherapy
Description: Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg qualifying session
Description: Qualifying session (2 mg oral alprazolam)
Study NCT04590768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein based meals
Description: various meal products: bread, soup and an occasional burgers
Study NCT04590768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matching control meals with whey protein and wheat bran
Description: various meal products: bread, soup and an occasional burgers
Study NCT02618382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
Study NCT02084927 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOT
Description: HBOT of 2 ATA for 90 minutes, for 60 treatments
Study NCT02084927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT of 2 ATA for 90 minutes, for 60 treatments
Study NCT04489303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Response App
Description: Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
Study NCT04489303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a workbook and online resources.
Study NCT02966496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acri.LISA366D multifocal aspheric IOLs
Description: The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
Study NCT02966496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TecnisZ9001 multifocal aspheric IOLs
Description: The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
Study NCT01010789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: flexible dose 150-250mg/day
Study NCT01010789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150-250mg/day; flexible dose
Study NCT01010789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo comparator
Study NCT02621463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilator (V60, Philips)
Description: The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
Study NCT01363011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Description: E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
Study NCT01363011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: COBI 150 mg tablet administered with food orally once daily
Study NCT01363011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: ATV 300 mg tablet administered orally once daily
Study NCT01363011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: DRV 800 mg tablet administered orally once daily
Study NCT01363011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTI
Description: Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
Study NCT03715686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wire localization
Description: Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo qualifying session
Description: Qualifying control session (oral placebo)
Study NCT04159181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral solution lactulose (20g lactulose/200mL water).
Study NCT04159181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picoprep
Description: Cathartic to accomplish an evacuation of the colonic content.
Study NCT04159181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (water)
Description: oral administration of Water (200mL).
Study NCT01205893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovasc Reducer
Description: Implantation of the Reducer
Study NCT01205893 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control - No device implanted
Study NCT01021631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
Study NCT01021631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
Study NCT04571333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi2000 Totally Implantable Cochlear Implant
Description: During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
Study NCT01645111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Study NCT01662362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Testing Donor Specimens with ESA Chagas
Description: Donors will be asked to return for a follow-up blood draw.
Study NCT02807779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion
Description: Participants will receive dexamethasone infusion following plain balloon angioplasty
Study NCT02807779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug coated balloon
Description: Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
Study NCT02807779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain balloon angioplasty
Description: Participants will receive plain balloon angioplasty only
Study NCT02618226 — intervention group
Intervention type: DEVICE
Intervention: Optic nerve ultrasound
Description: Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
Study NCT01140737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
Study NCT00116493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron-folic acid and mebendazole
Description: 100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children
Study NCT00116493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: 100 mg twice a day for 3 days; Iron-folic acid also given
Study NCT00116493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
Study NCT00116493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole + Multivitamin
Description: Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
Study NCT01134627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
Study NCT01134627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
Study NCT00610753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Behavior Therapy
Description: This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
Study NCT00610753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systems Family Therapy
Description: This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
Study NCT04276987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs-derived exosomes
Description: 5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
Study NCT02165605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HylaCare
Description: cream
Study NCT02165605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02414906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: Goal-directed therapy with fluids and dobutamine
Study NCT04365855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Elastography
Description: Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
Study NCT04365855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Clinical blood tests with a focus on liver function parameters and diabetes
Study NCT01711047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter Ablation
Description: In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
Study NCT01711047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
Study NCT02085356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect your family
Description: Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)